Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
Amicus Therapeutics (Nasdaq: FOLD) will host a conference call and live audio webcast on May 9, 2022, at 8:30 a.m. ET to discuss financial results for Q1 2022, covering the period ended March 31, 2022. Investors can participate by calling 877-303-5859 (U.S./Canada) or 678-224-7784 (international) and using conference ID 7867383. Additionally, a replay will be available for seven days post-call. The company focuses on developing innovative therapies for rare metabolic diseases and is dedicated to patient-centric care. For further information, visit their corporate website.
- Commitment to developing innovative treatments for rare metabolic diseases.
- Strong focus on patient-centric care.
- None.
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022.
Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7867383. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 7867383.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When will Amicus Therapeutics discuss its Q1 2022 financial results?
How can investors access the Amicus Therapeutics conference call?